Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.724 | 0.280 | 1 | 159714875 | upstream gene variant | G/A;T | snv |
|
0.800 | 1.000 | 4 | 2008 | 2018 | |||||||||
|
0.752 | 0.520 | 1 | 159715346 | upstream gene variant | A/G | snv | 0.13 |
|
0.800 | 1.000 | 3 | 2011 | 2019 | ||||||||
|
0.683 | 0.440 | 1 | 159713648 | splice region variant | C/A;G;T | snv | 4.4E-05; 5.1E-02; 4.0E-06 |
|
0.800 | 1.000 | 2 | 2013 | 2018 | ||||||||
|
0.602 | 0.680 | 1 | 159712443 | 3 prime UTR variant | C/T | snv | 0.30 |
|
0.700 | 1.000 | 5 | 2012 | 2014 | ||||||||
|
0.672 | 0.520 | 1 | 159713301 | 3 prime UTR variant | G/A | snv | 0.26 |
|
0.700 | 1.000 | 1 | 2013 | 2013 | ||||||||
|
1 | 159715525 | upstream gene variant | T/A;C;G | snv |
|
0.700 | 1.000 | 1 | 2012 | 2012 | |||||||||||
|
0.752 | 0.520 | 1 | 159715346 | upstream gene variant | A/G | snv | 0.13 |
|
Respiratory Tract Diseases; Immune System Diseases | 0.700 | 1.000 | 1 | 2011 | 2011 | |||||||
|
0.752 | 0.520 | 1 | 159715346 | upstream gene variant | A/G | snv | 0.13 |
|
Nervous System Diseases; Cardiovascular Diseases | 0.050 | 1.000 | 5 | 2013 | 2020 | |||||||
|
0.602 | 0.680 | 1 | 159712443 | 3 prime UTR variant | C/T | snv | 0.30 |
|
Mental Disorders | 0.040 | 1.000 | 4 | 2009 | 2018 | |||||||
|
0.602 | 0.680 | 1 | 159712443 | 3 prime UTR variant | C/T | snv | 0.30 |
|
Behavior and Behavior Mechanisms | 0.040 | 1.000 | 4 | 2009 | 2018 | |||||||
|
0.602 | 0.680 | 1 | 159712443 | 3 prime UTR variant | C/T | snv | 0.30 |
|
Behavior and Behavior Mechanisms | 0.040 | 1.000 | 4 | 2009 | 2018 | |||||||
|
0.683 | 0.440 | 1 | 159713648 | splice region variant | C/A;G;T | snv | 4.4E-05; 5.1E-02; 4.0E-06 |
|
Nervous System Diseases; Cardiovascular Diseases | 0.040 | 1.000 | 4 | 2006 | 2019 | |||||||
|
0.602 | 0.680 | 1 | 159712443 | 3 prime UTR variant | C/T | snv | 0.30 |
|
Nervous System Diseases; Cardiovascular Diseases | 0.030 | 1.000 | 3 | 2006 | 2020 | |||||||
|
0.776 | 0.320 | 1 | 159714396 | intron variant | T/A;C | snv | 0.28 |
|
Behavior and Behavior Mechanisms | 0.030 | 1.000 | 3 | 2015 | 2018 | |||||||
|
0.776 | 0.320 | 1 | 159714396 | intron variant | T/A;C | snv | 0.28 |
|
Mental Disorders | 0.030 | 1.000 | 3 | 2015 | 2018 | |||||||
|
0.776 | 0.320 | 1 | 159714396 | intron variant | T/A;C | snv | 0.28 |
|
Behavior and Behavior Mechanisms | 0.030 | 1.000 | 3 | 2015 | 2018 | |||||||
|
0.672 | 0.520 | 1 | 159713301 | 3 prime UTR variant | G/A | snv | 0.26 |
|
Cardiovascular Diseases | 0.020 | 0.500 | 2 | 2008 | 2014 | |||||||
|
0.672 | 0.520 | 1 | 159713301 | 3 prime UTR variant | G/A | snv | 0.26 |
|
Skin and Connective Tissue Diseases; Immune System Diseases | 0.020 | 1.000 | 2 | 2017 | 2018 | |||||||
|
0.672 | 0.520 | 1 | 159713301 | 3 prime UTR variant | G/A | snv | 0.26 |
|
Cardiovascular Diseases | 0.020 | 1.000 | 2 | 2006 | 2008 | |||||||
|
0.672 | 0.520 | 1 | 159713301 | 3 prime UTR variant | G/A | snv | 0.26 |
|
Behavior and Behavior Mechanisms | 0.020 | 0.500 | 2 | 2009 | 2015 | |||||||
|
0.672 | 0.520 | 1 | 159713301 | 3 prime UTR variant | G/A | snv | 0.26 |
|
Cardiovascular Diseases | 0.020 | 1.000 | 2 | 2006 | 2008 | |||||||
|
0.672 | 0.520 | 1 | 159713301 | 3 prime UTR variant | G/A | snv | 0.26 |
|
Behavior and Behavior Mechanisms | 0.020 | 0.500 | 2 | 2009 | 2015 | |||||||
|
0.672 | 0.520 | 1 | 159713301 | 3 prime UTR variant | G/A | snv | 0.26 |
|
Mental Disorders | 0.020 | 0.500 | 2 | 2009 | 2015 | |||||||
|
0.602 | 0.680 | 1 | 159712443 | 3 prime UTR variant | C/T | snv | 0.30 |
|
Neoplasms | 0.020 | 1.000 | 2 | 2010 | 2018 | |||||||
|
0.602 | 0.680 | 1 | 159712443 | 3 prime UTR variant | C/T | snv | 0.30 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.020 | 1.000 | 2 | 2013 | 2015 |